Next Article in Journal / Special Issue
Personalized Medicine’s Bottleneck: Diagnostic Test Evidence and Reimbursement
Previous Article in Journal / Special Issue
Ethics, Evidence and Economics in the Pursuit of “Personalized Medicine”
J. Pers. Med. 2014, 4(2), 147-162; doi:10.3390/jpm4020147
Article

Genetically Guided Statin Therapy on Statin Perceptions, Adherence, and Cholesterol Lowering: A Pilot Implementation Study in Primary Care Patients

1
, 2
, 1
, 3
, 4
, 1,4
 and 1,4,*
1 Center for Personalized and Precision Medicine, Duke University Medical Center, Durham, NC 27708, USA 2 Division of General Internal Medicine, Department of Medicine, University of Colorado Denver Anschutz Medical Campus, Aurora, CO 80045, USA 3 Division of General Internal Medicine, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA 4 Division of Cardiovascular Medicine, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
* Author to whom correspondence should be addressed.
Received: 19 December 2013 / Revised: 4 March 2014 / Accepted: 17 March 2014 / Published: 27 March 2014
(This article belongs to the Special Issue Bringing Personalized Medicine into Clinical Practice)
View Full-Text   |   Download PDF [654 KB, uploaded 27 March 2014]   |   Browse Figures

Abstract

Statin adherence is often limited by side effects. The SLCO1B1*5 variant is a risk factor for statin side effects and exhibits statin-specific effects: highest with simvastatin/atorvastatin and lowest with pravastatin/rosuvastatin. The effects of SLCO1B1*5 genotype guided statin therapy (GGST) are unknown. Primary care patients (n = 58) who were nonadherent to statins and their providers received SLCO1B1*5 genotyping and guided recommendations via the electronic medical record (EMR). The primary outcome was the change in Beliefs about Medications Questionnaire, which measured patients’ perceived needs for statins and concerns about adverse effects, measured before and after SLCO1B1*5 results. Concurrent controls (n = 59) were identified through the EMR to compare secondary outcomes: new statin prescriptions, statin utilization, and change in LDL-cholesterol (LDL-c). GGST patients had trends (p = 0.2) towards improved statin necessity and concerns. The largest changes were the “need for statin to prevent sickness” (p < 0.001) and “concern for statin to disrupt life” (p = 0.006). GGST patients had more statin prescriptions (p < 0.001), higher statin use (p < 0.001), and greater decrease in LDL-c (p = 0.059) during follow-up. EMR delivery of SLCO1B1*5 results and recommendations is feasible in the primary care setting. This novel intervention may improve patients’ perceptions of statins and physician behaviors that promote higher statin adherence and lower LDL-c.
Keywords: pharmacogenetics; personalized medicine; medication adherence; risk assessment; health behavior; hyperlipidemia pharmacogenetics; personalized medicine; medication adherence; risk assessment; health behavior; hyperlipidemia
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Export to BibTeX |
EndNote


MDPI and ACS Style

Li, J.H.; Joy, S.V.; Haga, S.B.; Orlando, L.A.; Kraus, W.E.; Ginsburg, G.S.; Voora, D. Genetically Guided Statin Therapy on Statin Perceptions, Adherence, and Cholesterol Lowering: A Pilot Implementation Study in Primary Care Patients. J. Pers. Med. 2014, 4, 147-162.

View more citation formats

Supplement

Related Articles

Article Metrics

Comments

Citing Articles

[Return to top]
J. Pers. Med. EISSN 2075-4426 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert